Skip to main content
Clinical Trials/NCT05312853
NCT05312853
Not yet recruiting
Not Applicable

Evaluating the Diagnostic and Predictive Value of Non-invasive Tests (NITs) on the Progression of Chronic Liver Disease.

Johannes Gutenberg University Mainz1 site in 1 country250 target enrollmentJanuary 15, 2024

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chronic Liver Disease
Sponsor
Johannes Gutenberg University Mainz
Enrollment
250
Locations
1
Primary Endpoint
Overall survival
Status
Not yet recruiting
Last Updated
2 years ago

Overview

Brief Summary

Primary objective is to study the relevance of non-invasive test (NITs) in predicting disease stage (diagnostic biomarker) and outcome (predictive biomarker) in patients with suspected or established liver disease and cirrhosis.

Detailed Description

Non-invasive tests (NITs) may complement and even reduce the need for liver biopsy in the diagnosis and follow up care of patients with chronic liver disease (CLD). NITs either include serum biomarkers (direct or indirect) or ultrasound-based tests, including vibration controlled transient elastography (VCTE), or a combination of both incorporated into several surrogate scores.

Registry
clinicaltrials.gov
Start Date
January 15, 2024
End Date
December 31, 2034
Last Updated
2 years ago
Study Type
Observational
Sex
All

Investigators

Sponsor
Johannes Gutenberg University Mainz
Responsible Party
Principal Investigator
Principal Investigator

Jörn M. Schattenberg

Prof. Dr.

Johannes Gutenberg University Mainz

Eligibility Criteria

Inclusion Criteria

  • Age ≥18 years
  • Clinically suspected chronic liver disease based on any of:
  • Patient with historical liver biopsy providing histological evidence of any liver disease or,
  • Patient undergoing liver biopsy for suspected chronic liver disease with biochemical and/or radiological findings consistent with liver disease or,
  • Patient with clinical and radiological evidence of cirrhosis (in absence of an alternative aetiology)
  • Patients with metabolic risk factors predisposing to CLD

Exclusion Criteria

  • Refusal or inability (lack of capacity) to give informed consent.
  • Age \< 18 years
  • An active malignancy.
  • Life expectation of \< 5 years.
  • Patients not meeting inclusion criteria or judged by the investigator to be unsuitable for inclusion in the study.

Outcomes

Primary Outcomes

Overall survival

Time Frame: 10 years

The primary objective of this observational study is to assemble a cohort of well-characterised patients with chronic liver disease (CLD) and to collect associated clinical information, biological samples and imaging data for cross-sectional and longitudinal analyses in order to robustly validate diagnostic and predictive non-invasive tests (NITs) for the diagnosis, risk assessment (prognosis) and monitoring of patients with liver disease. The primary outcome will be overall survival.

Secondary Outcomes

  • Liver-related events(10 years)

Study Sites (1)

Loading locations...

Similar Trials